468P PANIB 20139173: Randomized, multicentre phase II trial comparing fluorouracil, leucovorin and oxaliplatin (FOLFOX) plus panitumumab versus FOLFOX plus bevacizumab in patients with previously untreated, RAS wild-type (WT) metastatic colorectal cancer (mCRC)

Autor:	Christian D. Rolfo, K. Op de Beeck, Willem Lybaert, Wim Demey, Koen Hendrickx, H. Kalantari, Erik Fransen, G. Van Camp, Monika Peeters, K. Janssens, J. Decaestecker
Rok vydání:	2020
Předmět:	Oncology medicine.medical_specialty Bevacizumab Colorectal cancer business.industry Wild type Hematology medicine.disease Oxaliplatin FOLFOX Fluorouracil Internal medicine medicine Panitumumab In patient business medicine.drug
Zdroj:	Annals of Oncology. 31:S440
ISSN:	0923-7534
DOI:	10.1016/j.annonc.2020.08.579
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::2d05dc07fa9e8d9cf87f8eb28b0bf1f7 https://doi.org/10.1016/j.annonc.2020.08.579 Zobrazit plný text záznamu